文献速递肝病

COVID-19疫情对加拿大阿尔伯塔省酒精性肝炎或肝硬化住院的影响

Impact of the COVID-19 Pandemic on Hospitalizations for Alcoholic Hepatitis or Cirrhosis in Alberta, Canada.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-10-26

该研究基于加拿大阿尔伯塔省2018年3月至2020年9月的住院数据,比较COVID-19限制期(2020年4-9月)与之前阶段酒精性肝炎、酒精性肝硬化和非酒精性肝硬化住院的变化。结果显示,非酒精性和酒精性肝硬化每月入院率稳定,但酒精性肝炎入院率显著增加(疫情期间22.1/10,000例入院 vs 2020年3月前11.6/10,000例入院;P < .001)。非酒精性肝硬化患者2020年3月后院内死亡率降低(8.5% vs 11.5%;P = .033),酒精性肝硬化和酒精性肝炎的院内死亡率稳定。

要点

  • COVID-19疫情期间酒精性肝炎每月入院率显著增加。
  • 非酒精性和酒精性肝硬化每月入院率在疫情前后保持稳定。
  • 非酒精性肝硬化患者2020年3月后院内死亡率降低。

核心结论

  • COVID-19疫情前后非酒精性和酒精性肝硬化每月入院率稳定,但酒精性肝炎入院率显著增加。

研究设计与样本

  • 基于加拿大阿尔伯塔省2018年3月至2020年9月的省级住院和实验室数据库,使用经过验证的ICD-9和ICD-10编码算法识别肝相关住院,比较COVID-19限制期(2020年4-9月)与之前研究阶段,采用Joinpoint回归评估时间趋势。

主要发现

  • 研究期间共识别非酒精性肝硬化住院2916例、酒精性肝硬化住院2318例、酒精性肝炎住院1408例。
  • 酒精性肝炎队列平均每月入院率在疫情期间为22.1/10,000例入院,2020年3月前为11.6/10,000例入院,差异显著(P < .001)。
  • 非酒精性肝硬化患者2020年3月后院内死亡率为8.5%,低于之前的11.5%(P = .033)。
  • 酒精性肝硬化和酒精性肝炎的院内死亡率与疫情前相比保持稳定。

临床怎么用

  • 临床应关注COVID-19疫情期间酒精性肝炎入院增加的趋势,对酒精性肝病患者加强监测和干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Coronavirus disease 2019 (COVID-19) pandemic lockdown and restrictions had significant disruption to patient care. We aimed to evaluate the impact of COVID-19 restrictions on hospitalizations of patients with alcoholic and nonalcoholic cirrhosis as well as alcoholic hepatitis (AH) in Alberta, Canada. METHODS: We used validated International Classification of Diseases (ICD-9 and ICD-10) coding algorithms to identify liver-related hospitalizations for nonalcoholic cirrhosis, alcoholic cirrhosis, and AH in the province of Alberta between March 2018 and September 2020. We used the provincial inpatient discharge and laboratory databases to identify our cohorts. We used elevated alanine aminotransferase or aspartate aminotransferase, elevated international normalized ratio, or bilirubin to identify AH patients. We compared COVID-19 restrictions (April-September 2020) with prior study periods. Joinpoint regression was used to evaluate the temporal trends among the 3 cohorts. RESULTS: We identified 2916 hospitalizations for nonalcoholic cirrhosis, 2318 hospitalizations for alcoholic cirrhosis, and 1408 AH hospitalizations during our study time. The in-hospital mortality rate was stable in relation to the pandemic for alcoholic cirrhosis and AH. However, nonalcoholic cirrhosis patients had lower in-hospital mortality rate after March 2020 (8.5% vs 11.5%; P = .033). There was a significant increase in average monthly admissions in the AH cohort (22.1/10,000 admissions during the pandemic vs 11.6/10,000 admissions before March 2020; P < .001). CONCLUSIONS: Before and during COVID-19 monthly admission rates were stable for nonalcoholic and alcoholic cirrhosis; however, there was a significant increase in AH admissions. Because alcohol sales surged during the pandemic, future impact on alcoholic liver disease could be detrimental.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Shaheen AA, Kong K, Ma C, et al. Impact of the COVID-19 Pandemic on Hospitalizations for Alcoholic Hepatitis or Cirrhosis in Alberta, Canada. Clin Gastroenterol Hepatol. 2021. PMID: 34715379. doi:10.1016/j.cgh.2021.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。